Credicorp Ltd (BAP) is a good buy right now for a beginner-focused, long-term investor with $50,000-$100,000 to deploy. The stock has a constructive technical setup, supportive analyst sentiment, a favorable options skew, and no fresh negative news. I would rate it as a buy rather than a hold because the current price is still within an upward trend and the analyst target range sits meaningfully above the current share price.
BAP is in an uptrend: SMA_5 is above SMA_20 and SMA_20 is above SMA_200, which is a bullish long-term structure. The MACD histogram is positive at 3.423, though it is contracting, suggesting momentum is still positive but not accelerating. RSI_6 at 56.835 is neutral-to-bullish, showing the stock is not overbought. Price at 340.94 is just below R1 resistance at 349.478 and above the pivot at 328.694, which indicates the stock is holding near a breakout zone. Overall, the technical picture remains favorable for a long-term entry.

["Analyst price targets have been raised repeatedly, with JPMorgan at $415, UBS at $412, and HSBC upgrading to Buy.", "HSBC cited very strong Q1 results, low cost of risk, rising loan growth, and resilient margins.", "Macro backdrop described by HSBC is favorable, including strong domestic demand and supportive commodity conditions.", "Technical trend is bullish with SMA_5 > SMA_20 > SMA_200.", "No negative news in the recent week.", "Options positioning is bullish with a low put-call ratio."]
["No recent news catalysts in the last week, so near-term upside may be more gradual.", "MACD histogram is positive but contracting, indicating momentum is cooling somewhat.", "Current price is near resistance at 349.478, so upside may pause before extending.", "Hedge funds and insiders are neutral, with no notable buying trend.", "Financial snapshot data was unavailable, limiting a full latest-quarter fundamental review."]
Latest quarter financial data was not provided in usable form, so a full financial breakdown is unavailable. However, HSBC’s note says Q1 results were very strong, supported by low cost of risk, rising loan growth, and resilient margins. That points to healthy recent operating trends for the latest reported quarter, which appears to be Q1 2026 based on the timing of the analyst commentary.
Analyst sentiment is clearly positive and improving. JPMorgan raised its price target to $415 and kept Overweight on 2026-05-28. UBS raised its target to $412 and kept Buy on 2026-05-26. HSBC upgraded the stock to Buy from Hold on 2026-05-19 with a $350 target, citing strong Q1 results and favorable macro conditions. UBS also previously raised its target sharply from $318 to $408. The Wall Street pros view is constructive overall: multiple upgrades, higher targets, and positive operating commentary outweigh the lack of recent negative analyst views.